Statement: Both cohorts of the primary trial receive higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants.
Primary_evidence: INTERVENTION 1:    100 mg Q-122   Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days. INTERVENTION 2:    200 mg Q-122   Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days.
Secondary_evidence: INTERVENTION 1:    Treatment Period 1   Participants received AZD9496 - Variant A (100 mg). INTERVENTION 2:    Treatment Period 2   Participants received AZD9496 - Reference (100 mg).